Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. More Details
Mediocre balance sheet second-rate dividend payer.
Share Price & News
How has Dermapharm Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DMP is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: DMP's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: DMP exceeded the German Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: DMP exceeded the German Market which returned 0.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Dermapharm Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StDermapharm Holding SE Just Missed Earnings - But Analysts Have Updated Their Models
2 weeks ago | Simply Wall StIs Dermapharm Holding SE's (ETR:DMP) ROE Of 28% Impressive?
1 month ago | Simply Wall StDo Investors Have Good Reason To Be Wary Of Dermapharm Holding SE's (ETR:DMP) 1.8% Dividend Yield?
Is Dermapharm Holding undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DMP (€53.92) is trading below our estimate of fair value (€60.52)
Significantly Below Fair Value: DMP is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: DMP is poor value based on its PE Ratio (36.3x) compared to the XE Pharmaceuticals industry average (23.5x).
PE vs Market: DMP is poor value based on its PE Ratio (36.3x) compared to the German market (22.9x).
Price to Earnings Growth Ratio
PEG Ratio: DMP is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: DMP is overvalued based on its PB Ratio (9.8x) compared to the DE Pharmaceuticals industry average (6.2x).
How is Dermapharm Holding forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DMP's forecast earnings growth (19.7% per year) is above the savings rate (0.2%).
Earnings vs Market: DMP's earnings (19.7% per year) are forecast to grow slower than the German market (27.2% per year).
High Growth Earnings: DMP's earnings are forecast to grow, but not significantly.
Revenue vs Market: DMP's revenue (5.8% per year) is forecast to grow slower than the German market (5.9% per year).
High Growth Revenue: DMP's revenue (5.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DMP's Return on Equity is forecast to be high in 3 years time (30.4%)
How has Dermapharm Holding performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DMP has high quality earnings.
Growing Profit Margin: DMP's current net profit margins (10.3%) are lower than last year (10.9%).
Past Earnings Growth Analysis
Earnings Trend: DMP's earnings have grown by 10.3% per year over the past 5 years.
Accelerating Growth: DMP's earnings growth over the past year (8.8%) is below its 5-year average (10.3% per year).
Earnings vs Industry: DMP earnings growth over the past year (8.8%) underperformed the Pharmaceuticals industry 13.2%.
Return on Equity
High ROE: Whilst DMP's Return on Equity (26.61%) is high, this metric is skewed due to their high level of debt.
How is Dermapharm Holding's financial position?
Financial Position Analysis
Short Term Liabilities: DMP's short term assets (€412.0M) exceed its short term liabilities (€134.2M).
Long Term Liabilities: DMP's short term assets (€412.0M) do not cover its long term liabilities (€783.6M).
Debt to Equity History and Analysis
Debt Level: DMP's debt to equity ratio (199.7%) is considered high.
Reducing Debt: DMP's debt to equity ratio has reduced from 437.2% to 199.7% over the past 5 years.
Debt Coverage: DMP's debt is not well covered by operating cash flow (17.1%).
Interest Coverage: DMP's interest payments on its debt are well covered by EBIT (14.2x coverage).
What is Dermapharm Holding current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DMP's dividend (1.48%) is higher than the bottom 25% of dividend payers in the German market (1.12%).
High Dividend: DMP's dividend (1.48%) is low compared to the top 25% of dividend payers in the German market (3.64%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, DMP has been paying a dividend for less than 10 years.
Growing Dividend: DMP's dividend payments have increased, but the company has only paid a dividend for 2 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (53.9%), DMP's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: DMP's dividends in 3 years are forecast to be well covered by earnings (49.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Hans-George Feldmeier is the Chief Executive Officer and Chairman of the Management Board at Dermapharm Holding SE and also serves as Member of the Management Board from August 2017.
|CEO & Chairman of the Management Board||no data||no data||no data|
|CFO & Member of the Management Board||0.33yr||no data||no data|
|Member of the Management Board & Chief Business Development Officer||3.25yrs||no data||no data|
|Chief Marketing Officer & Member of Management Board||1.08yrs||no data||no data|
Experienced Management: DMP's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Dermapharm Holding SE's company bio, employee growth, exchange listings and data sources
- Name: Dermapharm Holding SE
- Ticker: DMP
- Exchange: XTRA
- Founded: 1991
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €2.903b
- Shares outstanding: 53.84m
- Website: https://www.ir.dermapharm.de
Number of Employees
- Dermapharm Holding SE
- Lil-Dagover-Ring 7
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|DMP||DB (Deutsche Boerse AG)||Yes||Bearer Shares||DE||EUR||Feb 2018|
|DMP||XTRA (XETRA Trading Platform)||Yes||Bearer Shares||DE||EUR||Feb 2018|
|DMPD||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Bearer Shares||GB||EUR||Feb 2018|
|0A5J||LSE (London Stock Exchange)||Yes||Bearer Shares||GB||EUR||Feb 2018|
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/24 21:01|
|End of Day Share Price||2020/11/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.